Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy

Adolfo Aleman et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Clinical course and genomic characterization of chimeric antigen receptor (CAR)+ T-cell lymphoma.
Clinical timeline showing absolute lymphocyte count during relevant clinical events, including cytokine release syndrome (CRS), respiratory syncytial virus (RSV), COVID-19, and rhinovirus infection, development of peripheral T-cell lymphoma (PTCL) (Panel A, left) (ULN: upper limit of normal; LLN: lower limit of normal). Facial skin lesions on presentation (day 196 post-CAR-T infusion, Panel A, middle) and 18 F-FDG PET/CT demonstrating hypermetabolic cutaneous lesions in the nose and cheeks (day 190, Panel A, right). Line graph illustrating CD3+ T cell composition following CAR-T infusion (Panel B). The blue line indicates endogenous T cells, the red line indicates tumor CAR-T cells, and the green line denotes non-malignant CAR-T expansion. The x-axis represents days post-CAR-T infusion. Visual representation of CAR-T insertion site in TIA1 (T-cell intracellular antigen 1) gene on chromosome 2 (Panel C, top). Longitudinal variant allele frequency (VAF) by whole genome sequencing from stem cell product, peripheral blood mononuclear cells (PBMC) prior to CAR-T therapy, and isolated peripheral blood tumor cells (Panel C, bottom left). Summary of genomic alterations (Panel C, bottom right).
See this image and copyright information in PMC

References

    1. Ozdemirli M, Loughney TM, Deniz E, et al. Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy. New England Journal of Medicine 2024;390(22):2074–82. - PubMed
    1. Perica K, Jain N, Scordo M, et al. CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53. New England Journal of Medicine 2025;392(6):577–83. - PMC - PubMed
    1. Harrison SJ, Touzeau C, Kint N, et al. CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma. New England Journal of Medicine 2025;392(7):677–85. - PubMed
    1. Braunstein Z, Waller A, Dotson E, et al. Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas. Leukemia & Lymphoma 2024;65(3):301–11. - PMC - PubMed
    1. Jain N, Zhao Z, Feucht J, et al. TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature 2023;615(7951):315–22. - PMC - PubMed